These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 30192782)

  • 1. Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial.
    Harrison SA; Dennis A; Fiore MM; Kelly MD; Kelly CJ; Paredes AH; Whitehead JM; Neubauer S; Traber PG; Banerjee R
    PLoS One; 2018; 13(9):e0203054. PubMed ID: 30192782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.
    Selvaraj EA; Mózes FE; Jayaswal ANA; Zafarmand MH; Vali Y; Lee JA; Levick CK; Young LAJ; Palaniyappan N; Liu CH; Aithal GP; Romero-Gómez M; Brosnan MJ; Tuthill TA; Anstee QM; Neubauer S; Harrison SA; Bossuyt PM; Pavlides M;
    J Hepatol; 2021 Oct; 75(4):770-785. PubMed ID: 33991635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort.
    Imajo K; Tetlow L; Dennis A; Shumbayawonda E; Mouchti S; Kendall TJ; Fryer E; Yamanaka S; Honda Y; Kessoku T; Ogawa Y; Yoneda M; Saito S; Kelly C; Kelly MD; Banerjee R; Nakajima A
    World J Gastroenterol; 2021 Feb; 27(7):609-623. PubMed ID: 33642832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis.
    Alsaqal S; Hockings P; Ahlström H; Gummesson A; Hedström A; Hulthe J; Johansson L; Niessen HG; Schoelch C; Schultheis C; Vessby J; Wanders A; Rorsman F; Ebeling Barbier C
    J Magn Reson Imaging; 2022 Aug; 56(2):368-379. PubMed ID: 34953171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis.
    Harrison SA; Marri SR; Chalasani N; Kohli R; Aronstein W; Thompson GA; Irish W; Miles MV; Xanthakos SA; Lawitz E; Noureddin M; Schiano TD; Siddiqui M; Sanyal A; Neuschwander-Tetri BA; Traber PG
    Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1183-1198. PubMed ID: 27778367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension.
    Chalasani N; Abdelmalek MF; Garcia-Tsao G; Vuppalanchi R; Alkhouri N; Rinella M; Noureddin M; Pyko M; Shiffman M; Sanyal A; Allgood A; Shlevin H; Horton R; Zomer E; Irish W; Goodman Z; Harrison SA; Traber PG;
    Gastroenterology; 2020 Apr; 158(5):1334-1345.e5. PubMed ID: 31812510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
    Jayakumar S; Middleton MS; Lawitz EJ; Mantry PS; Caldwell SH; Arnold H; Mae Diehl A; Ghalib R; Elkhashab M; Abdelmalek MF; Kowdley KV; Stephen Djedjos C; Xu R; Han L; Mani Subramanian G; Myers RP; Goodman ZD; Afdhal NH; Charlton MR; Sirlin CB; Loomba R
    J Hepatol; 2019 Jan; 70(1):133-141. PubMed ID: 30291868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.
    Loomba R; Kayali Z; Noureddin M; Ruane P; Lawitz EJ; Bennett M; Wang L; Harting E; Tarrant JM; McColgan BJ; Chung C; Ray AS; Subramanian GM; Myers RP; Middleton MS; Lai M; Charlton M; Harrison SA
    Gastroenterology; 2018 Nov; 155(5):1463-1473.e6. PubMed ID: 30059671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease.
    Costa-Silva L; Ferolla SM; Lima AS; Vidigal PVT; Ferrari TCA
    Eur J Radiol; 2018 Jan; 98():82-89. PubMed ID: 29279175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver Stiffness by Magnetic Resonance Elastography Predicts Future Cirrhosis, Decompensation, and Death in NAFLD.
    Gidener T; Ahmed OT; Larson JJ; Mara KC; Therneau TM; Venkatesh SK; Ehman RL; Yin M; Allen AM
    Clin Gastroenterol Hepatol; 2021 Sep; 19(9):1915-1924.e6. PubMed ID: 33010409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis.
    Jung J; Loomba RR; Imajo K; Madamba E; Gandhi S; Bettencourt R; Singh S; Hernandez C; Valasek MA; Behling C; Richards L; Fowler K; Sirlin CB; Nakajima A; Loomba R
    Gut; 2021 Oct; 70(10):1946-1953. PubMed ID: 33214165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis.
    Dennis A; Kelly MD; Fernandes C; Mouchti S; Fallowfield JA; Hirschfield G; Pavlides M; Harrison S; Chakravarthy MV; Banerjee R; Sanyal A
    Front Endocrinol (Lausanne); 2020; 11():575843. PubMed ID: 33584535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 2D Shear Wave Elastography, Transient Elastography, and MR Elastography for the Diagnosis of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Furlan A; Tublin ME; Yu L; Chopra KB; Lippello A; Behari J
    AJR Am J Roentgenol; 2020 Jan; 214(1):W20-W26. PubMed ID: 31714842
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis.
    Andersson A; Kelly M; Imajo K; Nakajima A; Fallowfield JA; Hirschfield G; Pavlides M; Sanyal AJ; Noureddin M; Banerjee R; Dennis A; Harrison S
    Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2451-2461.e3. PubMed ID: 34626833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
    Harrison SA; Wong VW; Okanoue T; Bzowej N; Vuppalanchi R; Younes Z; Kohli A; Sarin S; Caldwell SH; Alkhouri N; Shiffman ML; Camargo M; Li G; Kersey K; Jia C; Zhu Y; Djedjos CS; Subramanian GM; Myers RP; Gunn N; Sheikh A; Anstee QM; Romero-Gomez M; Trauner M; Goodman Z; Lawitz EJ; Younossi Z; ;
    J Hepatol; 2020 Jul; 73(1):26-39. PubMed ID: 32147362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a PEGylated Fibroblast Growth Factor 21 Variant Using Novel Preclinical Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Mouse Model of Nonalcoholic Steatohepatitis.
    Tang H; Li J; Zinker B; Boehm S; Mauer A; Rex-Rabe S; Glaser KJ; Fronheiser M; Bradstreet T; Nakao Y; Petrone T; Pena A; Villano M; Chow P; Malhi H; Charles ED; Hayes W; Ehman RL; Du S; Yin M
    J Magn Reson Imaging; 2022 Sep; 56(3):712-724. PubMed ID: 35092323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
    Rinella ME; Dufour JF; Anstee QM; Goodman Z; Younossi Z; Harrison SA; Loomba R; Sanyal AJ; Bonacci M; Trylesinski A; Natha M; Shringarpure R; Granston T; Venugopal A; Ratziu V
    J Hepatol; 2022 Mar; 76(3):536-548. PubMed ID: 34793868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-invasive assessment of hepatic fibrosis: comparison of MR elastography to transient elastography and intravoxel incoherent motion diffusion-weighted MRI.
    Fu F; Li X; Chen C; Bai Y; Liu Q; Shi D; Sang J; Wang K; Wang M
    Abdom Radiol (NY); 2020 Jan; 45(1):73-82. PubMed ID: 31372777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE
    Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
    Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K
    Hepatology; 2018 Jul; 68(1):349-360. PubMed ID: 29222917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.